FINHUB Insights

BDX · Q3 FY25 · Apr 1 – Jun 30, 2025

Becton Dickinson Q3 FY25: where the revenue came from and where it went

Becton Dickinson Q3 FY25: revenue $5.5B (+10% year over year). Net profit $0.6B. Largest cohort Medical $2.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 7, 2025 10-Q
Sankey diagram of Becton Dickinson's income statement for Q3 FY25: revenue of $5.5 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.5B +10% year over year
Gross profit$2.6B 48% margin
Operating profit$0.9B 16% margin
Net profit$0.6B 10% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 5.5 100% +10%
Medical 2.9 53%
Interventional 1.3 24%
Life Sciences 1.3 24%
Cost of revenue−2.953%
Gross profit2.648% margin+2pp
Research & development−0.35%−1pp
SG&A−1.324%+0pp
Other−0.12%+0pp
Operating profit0.916% margin+4pp
Tax−0.1
Interest & other costs−0.2
Net profit0.610%+1pp
Filing on EDGAR More quarters of BDX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters